ICTM logo
The STAMPEDE (MRC PR08) trial: Update on recent data and future plans

11 June 2014

The STAMPEDE Trial Management Group has been reflecting on recent publications and presentations at ASCO 2014 of randomised controlled trials assessing zoledronic acid or docetaxel for hormone-naïve prostate cancer.

The trial’s Independent Data Monitoring Committee (IDMC) performed their annual review of the docetaxel and zoledronic acid comparisons in on 6 June 2014. The Trial Steering Committee endorsed these recommendations on 9 June 2014.

The STAMPEDE Trial Management Group has issued an update on recent data

Further information: